Free Trial
NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

Ayala Pharmaceuticals logo
$0.11 +0.00 (+4.66%)
As of 04/25/2025 02:06 PM Eastern

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Key Stats

Today's Range
$0.05
$0.11
50-Day Range
$0.03
$0.11
52-Week Range
$0.00
$0.78
Volume
7,093 shs
Average Volume
2,288 shs
Market Capitalization
$4.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

Trump’s tariffs just split the AI market in two
Trump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying on cheap foreign hardware—just saw their costs shoot through the roof. For the other group of AI companies, they were just handed a massive competitive advantage. Make no mistake, AI as a whole is still a game-changer for the global economy. But within the AI sector, Trump’s tariffs have created a huge divergence.
Ayala unit expands cold storage network
Immunome: An Oncology Powerhouse In The Making
See More Headlines

ADXS Stock Analysis - Frequently Asked Questions

Ayala Pharmaceuticals' stock was trading at $0.0270 at the beginning of 2025. Since then, ADXS shares have increased by 307.4% and is now trading at $0.11.
View the best growth stocks for 2025 here
.

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) announced its earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The firm earned $0.25 million during the quarter.

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Acasti Pharma (ACST), Bristol-Myers Squibb (BMY) and

Company Calendar

Last Earnings
9/09/2021
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADXS
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.24 million
Price / Cash Flow
N/A
Book Value
($2.06) per share
Price / Book
-0.05

Miscellaneous

Free Float
42,364,000
Market Cap
$4.69 million
Optionable
Not Optionable
Beta
1.25
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:ADXS) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners